Evidence map›Paper›PMID 31442435›Full record

ArticleGastroenterology2019

The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.

Prasad Dandawate, Chandrayee Ghosh, Kanagaraj Palaniyandi, Santanu Paul, Sonia Rawal, Rohan Pradhan, Afreen Asif Ali Sayed, Sonali Choudhury, David Standing, Dharmalingam Subramaniam and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Targeting epigenetic regulators to overcome drug resistance in cancers.Signal transduction and targeted therapy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Prasad DandawateDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Chandrayee GhoshDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Kanagaraj PalaniyandiDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Santanu PaulDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Sonia RawalDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Rohan PradhanInterdisciplinary Science and Technology Research Academy, Abeda Inamdar Senior College, Camp, Pune, India.
Afreen Asif Ali SayedDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Sonali ChoudhuryDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
David StandingDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Dharmalingam SubramaniamDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Subhash B PadhyeDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas; Interdisciplinary Science and Technology Research Academy, Abeda Inamdar Senior College, Camp, Pune, India.
Sumedha GunewardenaDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas.
Sufi M ThomasDepartment of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas.
Maura O' NeilDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas.
Ossama TawfikDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas.
Danny R WelchDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Roy A JensenDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas.
Sally MaliskiSchool of Nursing, University of Kansas Medical Center, Kansas City, Kansas.
Scott WeirDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Tomoo IwakumaDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Shrikant AnantDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas. Electronic address: sanant@kumc.edu.
Animesh DharDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas. Electronic address: adhar@kumc.edu.
The University of Kansas Cancer Center · USUniversity of Kansas Medical Center · USSri Devaraj Urs Academy of Higher Education and Research · IN

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Transgenic and Gener-Targeting CoreP20GM104936 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SAADI, IRFAN · 2012 to 2016
$10.9M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Bitter Melon Component and Colon Cancer PreventionR01CA190291 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANANT, SHRIKANT, UMAR, SHAHID · 2014 to 2018
$2.7M
Dietary Prevention of CancerR01CA109269 · NCI · WASHINGTON UNIVERSITY · PI ANANT, SHRIKANT · 2005 to 2013
$2.7M
Novel Dual Notch/PXR Targeting for Colon Cancer TherapyR01CA182872 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANANT, SHRIKANT, WEIR, SCOTT JAMES · 2014 to 2018
$2.6M
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axisR01CA214916 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI IWAKUMA, TOMOO · 2018 to 2022
$1.8M
Chemoprevention of Pancreatic Cancer by EGCGR01CA125262 · NCI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI DHAR, ANIMESH · 2008 to 2012
$1.7M
The role of MDM2-MTBP axis in cancer metastasisR01CA174735 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI IWAKUMA, TOMOO · 2014 to 2018
$1.6M
RNA Binding Proteins in CancerR01CA135559 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ANANT, SHRIKANT · 2009 to 2013
$1.5M
Pancreatic Cancer: Crocetin as a Novel Therapeutic ApproachR01CA151727 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DHAR, ANIMESH · 2011 to 2013
$785k
NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA109269NCI NIH HHS R01 CA125262NCI NIH HHS R01 CA135559NCI NIH HHS R01 CA151727NCI NIH HHS R01 CA174735NCI NIH HHS R01 CA182872NCI NIH HHS R01 CA190291NCI NIH HHS R01 CA214916NICHD NIH HHS U54 HD090216NIGMS NIH HHS P20 GM104936
6 · The paper itself

Abstract

BACKGROUND &

aimsThe histone lysine demethylase 3A (KDM3A) demethylates H3K9me1 and H3K9Me2 to increase gene transcription and is upregulated in tumors, including pancreatic tumors. We investigated its activities in pancreatic cancer cell lines and its regulation of the gene encoding doublecortin calmodulin-like kinase 1 (DCLK1), a marker of cancer stem cells.

methodsWe knocked down KDM3A in MiaPaCa-2 and S2-007 pancreatic cancer cell lines and overexpressed KDM3A in HPNE cells (human noncancerous pancreatic ductal cell line); we evaluated cell migration, invasion, and spheroid formation under hypoxic and normoxic conditions. Nude mice were given orthotopic injections of S2-007 cells, with or without (control) knockdown of KDM3A, and HPNE cells, with or without (control) overexpression of KDM3A; tumor growth was assessed. We analyzed pancreatic tumor tissues from mice and pancreatic cancer cell lines by immunohistochemistry and immunoblotting. We performed RNA-sequencing analysis of MiaPaCa-2 and S2-007 cells with knockdown of KDM3A and evaluated localization of DCLK1 and KDM3A by immunofluorescence. We analyzed the cancer genome atlas for levels of KDM3A and DCLK1 messenger RNA in human pancreatic ductal adenocarcinoma (PDAC) tissues and association with patient survival time.

resultsLevels of KDM3A were increased in human pancreatic tumor tissues and cell lines, compared with adjacent nontumor pancreatic tissues, such as islet and acinar cells. Knockdown of KDM3A in S2-007 cells significantly reduced colony formation, invasion, migration, and spheroid formation, compared with control cells, and slowed growth of orthotopic tumors in mice. We identified KDM3A-binding sites in the DCLK1 promoter; S2-007 cells with knockdown of KDM3A had reduced levels of DCLK1. HPNE cells that overexpressed KDM3A formed foci and spheres in culture and formed tumors and metastases in mice, whereas control HPNE cells did not. Hypoxia induced sphere formation and increased levels of KDM3A in S2-007 cells and in HPNE cells that overexpressed DCLK1, but not control HPNE cells. Levels of KDM3A and DCLK1 messenger RNA were higher in human PDAC than nontumor pancreatic tissues and correlated with shorter survival times of patients.

conclusionsWe found human PDAC samples and pancreatic cancer cell lines to overexpress KDM3A. KDM3A increases expression of DCLK1, and levels of both proteins are increased in human PDAC samples. Knockdown of KDM3A in pancreatic cancer cell lines reduced their invasive and sphere-forming activities in culture and formation of orthotopic tumors in mice. Hypoxia increased expression of KDM3A in pancreatic cancer cells. Strategies to disrupt this pathway might be developed for treatment of pancreatic cancer.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCarcinogenesisCarcinoma, Pancreatic DuctalCell Line, TumorDatasets as TopicDNA MethylationDoublecortin-Like KinasesFemaleGene Knockdown TechniquesHumansIntracellular Signaling Peptides and ProteinsJumonji Domain-Containing Histone DemethylasesMaleMiceMiddle AgedDCLK1 protein, humanDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsJumonji Domain-Containing Histone DemethylasesKDM3A protein, humanProtein Serine-Threonine KinasesEpigeneticsGene RegulationOncogeneRepression

Identifiers

PMID31442435
PMCPMC6878178
OpenAlexW2969757932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.